

## Colorectal

### Metastatic

### Locally Advanced

#### 2nd Line

#### 1-3 Lung Nodules Amenable to Ablation

None at this time

**GI0022**  
[Phase I/Ib Global Multicenter Open-Label Umbrella Study Evaluating Safety & Efficacy of Targeted Therapies in Subpopulations of Patients w/ Metastatic Colorectal Cancer \(INTRINSIC\)](#)  
  
PI: Fisher  
Sponsor: F. Hoffmann-La Roche Ltd

**COR0023**  
[Phase II Randomized Open Label Study Evaluating the Safety & Efficacy of Magrolimab in Combination w/ Bevacizumab & FOLFIRI vs Bevacizumab & FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer \(CRC\)](#)  
  
PI: Fisher  
Sponsor: Gilead Sciences, Inc.

**GI0025**  
[Phase I Study to Evaluate Safety Tolerability Pharmacokinetics & Preliminary Antitumor Activity of PEEL-224 in Advanced Solid Tumors](#)  
  
PI: Fisher  
Sponsor: PEEL Therapeutics, Inc.

**COR0026**  
Phase I/II First-in-Human Study of BMS-986288 Alone & in Combination w/ Nivolumab in Advanced Malignant Tumors  
  
PI: Holden  
Sponsor: Bristol-Myers Squibb

**SARCOMA0058**  
[Phase III Transbronchial Microwave Ablation Using Robotic-Assisted Bronchoscopy in Oligometastatic Tumors in the Lung](#)  
  
PI: Bedi  
Sponsor: NeuWave Therapeutics, Inc. (Part of J&J Medical Devices Division)

**VAR0251**  
Phase I Safety & Efficacy of LYL845 in Adults w/ Relapsed &/or Refractory Metastatic or Locally Advanced Melanoma & Selected Solid Tumor Malignancies  
  
PI: Betof Warner  
Sponsor: Lyell Immunopharma Inc.

**GI0030**  
Phase I/II Open-Label Study to Investigate the Safety Tolerability Pharmacokinetics Pharmacodynamics & Preliminary Antitumor Activity of AT-1965 in Advanced Refractory or Recurrent Solid Tumors  
  
PI: Goyal  
Sponsor: Alyssum Therapeutics Inc.

**KEY**

Pending	Optional Path	Extension Study
Open for Enrollment	<a href="#">Link</a> Trial Posting	Immunotherapy
Observational Study	Enrollment on Hold	